ReviewInflammopharmacology2022
Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.
Review in Inflammopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Cys-loop receptors on cannabinoids: All high?Frontiers in physiology · 2022Pooled it
- Same-Day Sedative and Night-Time Sleep Effects Following Combined Cannabinoid Formulations: A Randomised-Controlled Trial.Clinical drug investigation · 2025Trial
- Effects and safety of a CBD-richFrontiers in pharmacology · 2025Trial
- Ten-year outcomes of medical cannabis for chronic low back pain: opioid reduction, pain relief, and functional improvement in 1,000 patients.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Inside the Minds of Professional and Elite Athletes: A Qualitative Exploration of Perspectives on Cannabinoid Use in Contact Sports.Sports health · 2026Article
- Phytocannabinoids as epigenetic regulators: bridging DNA methylation and redox homeostasis in glioblastoma.Journal of applied genetics · 2026Article
- Article
- Reasons for Using Cannabis Among Adults in the United States: Associations with Demographics, Health Behaviors, Chronic Conditions, and Legal Status.International journal of environmental research and public health · 2026Article
- Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study.Journal of psychopharmacology (Oxford, England) · 2026Article
- CARE - A Retrospective, Dual-Cohort, 24-Week Real-World Study from the German Pain e-Registry on the Effectiveness and Safety of CBD-Dominant Oral Cannabis Extracts versus THC/Dronabinol in Older Patients with Chronic Pain.Journal of pain research · 2026Article
- Cannabinoids and ADHD: a New Frontier in Neuropharmacology?Journal of molecular neuroscience : MN · 2025Review
- Cannabinoids in neuropathic pain treatment: pharmacological insights and clinical outcomes from recent trials.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The AhR Is a Critical Regulator of the Pulmonary Response to Cannabis Smoke.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Article
- Trends in Antidepressant, Anxiolytic, and Cannabinoid Use Among Italian Elite Athletes (2011-2023): A Longitudinal Anti-Doping Analysis.Sports (Basel, Switzerland) · 2025Article
- The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis.Systematic reviews · 2025Article
- Exploring Natural Analgesics for Chronic Pain Management: Cannabinoids and other Phytoconstituents.Current medicinal chemistry · 2025Review
- Comparative Study of Gas and Liquid Chromatography Methods for the Determination of Underivatised Neutral and Acidic Cannabinoids and Cholesterol.Molecules (Basel, Switzerland) · 2024Article
- Anxiety Modulation by Cannabinoids-The Role of Stress Responses and Coping.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination tetrahydrocannabinol (THC)/cannabidiol (CBD) medicines or CBD-only medicines are prospective treatments for chronic pain, stress, anxiety, depression, and insomnia. THC and CBD increase signaling from cannabinoid receptors, which reduces synaptic transmission in parts of the central and peripheral nervous systems and reduces the secretion of inflammatory factors from immune and glial cells. The overall effect of adding CBD to THC medicines is to enhance the analgesic effect but counteract some of the adverse effects. There is substantial evidence for the effectiveness of THC/CBD combination medicines for chronic pain, especially neuropathic and nociplastic pain or pain with an inflammatory component. For CBD-only medication, there is substantial evidence for stress, moderate evidence for anxiety and insomnia, and minimal evidence for depression and pain. THC/CBD combination medicines have a good tolerability and safety profile relative to opioid analgesics and have negligible dependence and abuse potential; however, should be avoided in patients predisposed to depression, psychosis and suicide as these conditions appear to be exacerbated. Non-serious adverse events are usually dose-proportional, subject to tachyphylaxis and are rarely dose limiting when patients are commenced on a low dose with gradual up-titration. THC and CBD inhibit several Phase I and II metabolism enzymes, which increases the exposure to a wide range of drugs and appropriate care needs to be taken. Low-dose CBD that appears effective for chronic pain and mental health has good tolerability and safety, with few adverse effects and is appropriate as an initial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.